צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: MAIA Biotechnology (MAIA)

MAIA Biotechnology is optimizing biomaterial supplies for the development of immuno-oncology agents to maintain margins. The trailing four-quarter annual revenue growth rate confirms the trend, with the figure settling at 0.00. The company is integrating AI into drug synthesis, although medical decisions remain with physicians. Currently, the firm is developing targeted telomere activation methods to combat aggressive lung cancer.
MAIA Biotechnology, Inc. (MAIA) - פילוחי מדדים ודוחות פיננסיים

This indicator measures commercial revenue dynamics over a rolling year, neutralizing quarterly reporting gaps. By analyzing comparable year-over-year sales growth over 12 months on GURU.Markets, an investor assesses the fundamental scale of the business. The metric captures the percentage change in revenue, determining the stability of cash flows. For MAIA Biotechnology (MAIA), these levels depend on the efficiency of collaboration with external research centers. Controlling outsourcing costs directly impacts the final financial performance.